Join us for interview with Dr. Joana Reis on "How #AI Innovations Are Transforming #BreastCancer Screening." We will explore how AI-driven advancements are transforming #breast #cancer screening and early detection for women with #densebreast tissue.

Dr. Rafael Rosell discusses advancements in the treatment of non-small cell #lungcancer with #KRASG12C mutation and the encouraging results from the KROCUS study highlighted an 81.8% objective response rate.

#Datopotamab deruxtecan (#DatoDXd) has been granted Priority Review from #FDA for advanced EGFR+ non-small cell #lungcancer (#NSCLC) following prior therapies. Pooled analysis showed a 42% objective response rate and a 7-month MDR #Datopotamabderuxtecan

#FDA has approved #Datroway (#datopotamab #deruxtecan-dlnk) for adult patients with unresectable or metastatic HR+, HER2- #breastcancer. This innovative #TROP2-directed antibody-drug conjugate (#ADC) provides a much-needed treatment option for patients

#FDA has approved novel combination therapy using #sotorasib and #panitumumab for adults with #KRASG12C-mutated #colorectalcancer (#mCRC). This combo targeting both KRAS and EGFR pathways improves progression-free survival compared to standard therapies

Oncolytics Biotech received approval to advance GOBLET study, evaluating #pelareorep with #mFOLFIRINOX for metastatic #pancreatic #cancer. Promising early results highlight pelareorep\u2019s potential to improve outcomes for #pancreaticcancer patients...

How #ArtificialIntelligence Could Overcome Data Scarcity to Transform #Medicine #AI can play a crucial role in #drugdiscovery, but the lack of sufficient data in this area remains a significant obstacle. Interview with Adityo Prakash, CEO of Verseon

Ariceum Therapeutics announced that #FDA has cleared its investigational new drug application to commence a Phase I/II clinical trial of its proprietary radiolabelled peptide, 225Ac-SSO110 (#satoreotide), in patients with small cell #lungcancer (#SCLC)

🌐 #IoMT: A Revolution in #Healthcare Needs a New Security Model 🔒 Darron Antill, CEO of DA, highlights in his latest article, "The #Internet of #Medical Things needs a new security model to fulfil its potential." Share your thoughts in comments!

#FDA has approved tirzepatide (#Zepbound) as the first medication for obstructive #sleepapnea in adults with #obesity. #Tirzepatide achieved an average #weightloss of up to 20%, along with a reduction of at least 25 breathing interruptions per hour.

#FDA approved #BRAFTOVI (#encorafenib) with #cetuximab and #mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic #colorectal #cancer. The P3 trial showed higher response rates (61% vs 40%) and longer response duration for #ColorectalCancer.

We’re excited to announce an interview with Carter Keller, Head of GigaGen, as we delve into the advancements of #GIGA2339, the first recombinant #polyclonal drug candidate in development for the treatment of #hepatitis B virus (#HBV) infection.

#Ribociclib (#Kisqali®) combined with endocrine therapy demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/#HER2- early #breastcancer patients, based on Phase III #NATALEE trial data presented at #SABCS24.

We are excited to announce interview with Dr. Sara Naseri, CEO of Qvin, on #QPad technology—the first #FDA-approved menstrual #bloodtest. We will dive into how Q-Pad is transforming women's healthcare by enabling the early detection of #cervicalcancer.

#PATINA Trial shows that adding #palbociclib (#IBRANCE) to standard maintenance therapy extends progression-free survival (PFS) in HR+, #HER2+ metastatic #breastcancer. Presented at #SABCS24, these findings demonstrate a more than 15-month gain in PFS.

🌟 Join Us for an Exclusive #ONCOLife Interview We are excited to announce a special interview session with Dr. Sara Naseri, CEO of #Qvin, the visionary behind #QPad technology—the first #FDA-approved menstrual #bloodtest.

The latest findings presented at #SABCS24 from #OlympiA trail reveal that patients with germline #BRCA+, #HER2- #breastcancer who received one year of the oral #PARPinhibitor #olaparib (#Lynparza) after standard therapy saw notably improved outcomes.

The promising results from a Phase 2 study show #NKTR255 improved six-month complete response rates in relapsed large B-cell #lymphoma to 73%. It enhanced #CARTcell expansion and durability, prompting stable responses to become complete responses.

#AbbVie announced plans to acquire #Nimble in a $200 million deal. The acquisition brings Nimble’s pioneering #oralpeptide #IL23R inhibitor, currently in preclinical development for #psoriasis, and a robust portfolio of #autoimmune disease therapies.

Elevation Oncology Partners with Synaffix in $368M Deal to develop #EO1022, a #HER3-targeting #AntibodyDrugConjugate (#ADC). This collaboration aims to create a highly effective and safer therapy for HER3-positive #solidtumors.